Annovis Bio, Inc. — Form 8-K
Filed October 30, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
On October 29, 2026, Annovis Bio (market cap ~$36.1M) received notice from NYSE that it failed continued listing standards under Section 802.01B because its 30-day average market capitalization (~$48.4M) and stockholders' equity (deficit of ~$4.3M as of June 30, 2026) both fell below $50M. The company has 45 days to submit a remediation plan and 9 months from notice to regain compliance; stock will trade with '.BC' indicator but remain listed during the cure period. Failure to submit a timely plan, achieve acceptance, or meet standards by month 9 will trigger delisting procedures.
Why this rating
Near-existential threat: company faces delisting if it cannot raise capital or achieve business milestones within 9 months. Market cap ~$36M is below threshold, stockholders' deficit of $4.3M is material to this size. Delisting would severely impair liquidity and ability to fundraise—business-changing risk.
Price action (we called it negative)
before filing · preread $1.15 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.